NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 184 filers reported holding NEVRO CORP in Q3 2017. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $500,028 | -24.4% | 26,016 | 0.0% | 0.02% | -30.3% |
Q2 2023 | $661,327 | -29.7% | 26,016 | 0.0% | 0.03% | -26.7% |
Q1 2023 | $940,478 | -8.7% | 26,016 | 0.0% | 0.04% | -26.2% |
Q4 2022 | $1,030,234 | -15.0% | 26,016 | 0.0% | 0.06% | -24.7% |
Q3 2022 | $1,212,000 | +6.3% | 26,016 | 0.0% | 0.08% | +17.4% |
Q2 2022 | $1,140,000 | -39.4% | 26,016 | 0.0% | 0.07% | -25.8% |
Q1 2022 | $1,882,000 | -10.8% | 26,016 | 0.0% | 0.09% | +17.7% |
Q4 2021 | $2,109,000 | -30.4% | 26,016 | 0.0% | 0.08% | -41.5% |
Q3 2021 | $3,028,000 | -29.8% | 26,016 | 0.0% | 0.14% | -37.2% |
Q2 2021 | $4,313,000 | +18.8% | 26,016 | 0.0% | 0.22% | +28.7% |
Q1 2021 | $3,629,000 | -19.4% | 26,016 | 0.0% | 0.17% | -16.1% |
Q4 2020 | $4,503,000 | +24.3% | 26,016 | 0.0% | 0.20% | -4.8% |
Q3 2020 | $3,624,000 | +16.6% | 26,016 | 0.0% | 0.21% | -2.8% |
Q2 2020 | $3,108,000 | +19.5% | 26,016 | 0.0% | 0.22% | +4.4% |
Q1 2020 | $2,601,000 | -14.9% | 26,016 | 0.0% | 0.21% | +2.5% |
Q4 2019 | $3,058,000 | +36.7% | 26,016 | 0.0% | 0.20% | +70.3% |
Q3 2019 | $2,237,000 | +32.6% | 26,016 | 0.0% | 0.12% | +71.0% |
Q2 2019 | $1,687,000 | +3.8% | 26,016 | 0.0% | 0.07% | 0.0% |
Q1 2019 | $1,626,000 | +60.7% | 26,016 | 0.0% | 0.07% | +11.3% |
Q4 2018 | $1,012,000 | -31.8% | 26,016 | 0.0% | 0.06% | -23.5% |
Q3 2018 | $1,483,000 | -28.6% | 26,016 | 0.0% | 0.08% | -50.9% |
Q2 2018 | $2,077,000 | -7.9% | 26,016 | 0.0% | 0.16% | +22.2% |
Q1 2018 | $2,255,000 | +25.6% | 26,016 | 0.0% | 0.14% | +14.4% |
Q4 2017 | $1,796,000 | -24.0% | 26,016 | 0.0% | 0.12% | 0.0% |
Q3 2017 | $2,364,000 | +25.4% | 26,016 | +2.7% | 0.12% | +16.8% |
Q2 2017 | $1,885,000 | -20.6% | 25,323 | 0.0% | 0.10% | -38.4% |
Q1 2017 | $2,373,000 | +29.0% | 25,323 | 0.0% | 0.16% | +28.1% |
Q4 2016 | $1,840,000 | -28.8% | 25,323 | +2.3% | 0.13% | -21.5% |
Q3 2016 | $2,583,000 | +41.5% | 24,744 | 0.0% | 0.16% | +27.3% |
Q2 2016 | $1,825,000 | +31.1% | 24,744 | 0.0% | 0.13% | +40.7% |
Q1 2016 | $1,392,000 | -16.6% | 24,744 | 0.0% | 0.09% | -22.9% |
Q4 2015 | $1,670,000 | +60.3% | 24,744 | +10.2% | 0.12% | +51.3% |
Q3 2015 | $1,042,000 | -71.2% | 22,459 | -66.7% | 0.08% | -69.0% |
Q2 2015 | $3,622,000 | – | 67,378 | – | 0.25% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Iron Triangle Partners LP | 562,833 | $40,710,000 | 4.84% |
Altium Capital Management LP | 77,000 | $5,569,000 | 1.86% |
PFM Health Sciences, LP | 649,513 | $46,979,000 | 1.76% |
Rock Springs Capital Management LP | 721,500 | $52,186,000 | 1.31% |
Integral Health Asset Management, LLC | 50,000 | $3,617,000 | 0.94% |
Redmile Group, LLC | 411,017 | $29,729,000 | 0.93% |
K2 PRINCIPAL FUND, L.P. | 114,800 | $8,303,000 | 0.72% |
Connacht Asset Management LP | 18,762 | $1,357,000 | 0.70% |
Perceptive Advisors | 477,037 | $34,504,000 | 0.69% |
ArrowMark Colorado Holdings LLC | 855,439 | $61,874,000 | 0.54% |